新丝路控股集团_Providing professional financial news and data related to 新丝路控股集团, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

Finance
V.S. INT'L (01002.HK): Expects Interim Profit of USD 3,000,000-4,000,000, Markedly Up from the Same Period Last Year
Finance
HENGRUI PHARMA (01276.HK): SHR-7590 Injection Receives Drug Clinical Trial Approval Notice for Ulcerative Colitis and Crohn's Disease
Finance
CAPINFO (01075.HK): Expects Interim Results to Swing to Loss of Approximately RMB 30-50 Million
Finance
CH TIANBAO GP (01427.HK): Expects Interim Net Loss to Widen to RMB 60-70 Million on Reduced Revenue
Finance
MULTIFIELD INTL (00898.HK): Expects Interim Profit to Fall to Approximately HK$ 100-120 Million on Lower Fair Value Gains on Financial Assets
Finance
HENGRUI PHARMA (01276.HK): HRS-4729 Injection Approved for Phase II Clinical Trial in Type 2 Diabetes
Finance
CHUANGLIAN HOLD (02371.HK): Zhang Jie Resigns as Executive Director, Gao Rui Appointed to Replace Him, Effective 12 August 2026
Finance
DREAM INT'L (01126.HK): Expects Interim Net Profit to Decrease by 25%-35% on Higher Labor and Raw Material Costs
Finance
HERBS GROUP (02593.HK): Expects Interim Net Loss to Narrow by 40%-53% on Lower Advertising and Promotion Expenses
Finance
TH MEDICAL-B (02697.HK): Wins Bidding for Yunnan Agricultural University Research Equipment Project, Deal Value RMB 2.8 Million

Scan QR Code

Download App